OBJECTIVES: The aim of this study was to evaluate the prevalence of falls and its association with clinical data, disease-related outcomes and physical performance tests in RA patients.

METHODS: Cross-sectional study including patients with RA, followed in the Rheumatology Department over a period of 1 month in 2018. The following parameters were evaluated: clinical aspects; fall occurrence in the previous 12 months; pain on a visual analogue scale (VAS); RA disease activity. Physical performance tests were also compared for total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB) and Lipoprotein A (LpA). Additionally, an ultrasonographic measurement of intima-media thickness (IMT) of carotids was performed.

RESULTS: Forty-eight patients were enrolled, the average age was 55.8 ± 13.9 and the sex ratio was 0.14. The average disease duration was 13.49 years ± 9.12. The average DAS28 was 4.63 ± 1.19 and HAQ was 0.77 ± 0.88. Falls were reported by 44.7% of patients; 27.7% had one fall and 17% had ≥ 2 falls. Patients had a fractures history in 10.9% of cases and dislocations in 6.5% of cases. The HAQ (p=0.04) and c reactive protein (p<0.01) was associated with fall history; the other parameters (Gender, number of medications, age, disease activity and physical tests) showed no associations with history of falls. Physical performance decreased to 58.4% for TUG test, 61.7% for OST and 36.2% for SNT. The worst performance in physical tests (TUG, OST and SNT) was associated with older age, higher erythrocyte sedimentation rate, higher HAQ, and increased DAS28 (p<0.05). In addition, hips and especially knees involvement was significantly associated with TUG (p=0.03) and OST test (p=0.003). TUG test was significantly associated with depression (p<0.04). The OST test was associated with higher disease duration (p=0.004), VAS (p=0.006) and tender joints (p=0.001). There was no association between number of falls and any of the physical performance tests.

CONCLUSION: It was observed that the occurrence of falls is quite common in this population. The occurrence of falls in this sample of rheumatoid arthritis patients bears no relation to disease activity or physical performance tests. But, falls were associated with functional capacity.


Disclosure of Interests: None declared


THU0132

EVALUATION OF CARDBIOVASCULAR RISK FACTORS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH BIOLOGICAL AGENTS: 3-MONTH FOLLOW-UP

Giorgos Papamichail1, Theodora Markatezi2, Athanasios Georgiadis3, Vasileios Xydiss, Haralampos Milionis, Alexandros Drosos, Paraskovi Voulgi, Internal Medicine, University of Ioannina, Greece, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece; 2 Rheumatology Clinic, University of Ioannina, Ioannina, Greece, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece; 3 Radiology, University of Ioannina, Greece, Department of Radiology, Medical School, University of Ioannina, Ioannina, Greece

BACKGROUND: Systemic inflammation is an additional and independent predictor of cardiovascular disease (CVD) in rheumatoid arthritis (RA). It is worth mentioning that lipid levels, blood pressure and other major risk factors of CVD constitute a wide field of investigation in case of treatment with biological disease-modifying anti-rheumatic drugs (DMARDS).

OBJECTIVES: The aim of this study is to assess the impact of biological agents on markers of CVD risk in patients with RA.

METHODS: This is a prospective, observational study which included biologic-naive RA patients treated with synthetic DMARDs, who had a negative history of CVD. Thirty-one patients and 31 healthy matched-controls (for gender, age and smoking) were compared for total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (TGs), Apolipoprotein A1 (ApoA1), Apolipoprotein B (ApoB) and Lipoprotein A (LpA). Additionally, an ultrasonographic measurement of intima-media thickness (IMT) of carotids was performed by an experienced sonographer to all patients in order to detect the presence of atherosclerosis at baseline. Furthermore, in a subgroup of 19 of these 31 RA patients, the parameters we previously reported (except for IMT) were compared between baseline and a 3-month follow-up. We also compared disease activity indexes (disease activity score (DAS28), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)) at these predefined time-points.

RESULTS: As regards the demographic characteristics of 31 RA patients, the mean (SD) age was 54.7 (14.0) years, disease duration was 4.5 (1.3) years, there were 11 (35.5%) men and 20 (64.5%) women and 6 (19.3%) smokers. As far as the radiographic profile of patients is concerned, 17 (54.8%) were RF(+)- and 8 (25.8%) ACPA(+). The comparison of the parameters between RA patients and matched-controls revealed no increase in RA patients. The verified AH was present in 7 (23.3%) patients, the presence of RF in 9 patients, the presence of CRP in 5 patients. There were no differences in the range of received therapy, but the dose of prednisone was higher in the MS+ group (7.8±3.5 vs 6.4±3.9, p<0.05). Systolic blood pressure (BP) was higher in the MS+ group (128±17.3) vs MS- (119±15.9). The level of BP correlated (p<0.05) with the severity of pain. The verified AH was present in 42 (71.2%) patients of the MS+ group (1 stage -2, 2 stage -24, 3 stage -16 patients) and in 3 (7.3%) patients of the MS- group (1 stage in 1 patient, 2 stages in 2 patients). The cholesterol level was higher in the MS+ group 5.1±1.1 compared with the MS- group 4.6±0.6 (p<0.01). There was a persistent tendency (p<0.01) in increasing of the mass index of the left ventricle myocardium according to echocardiogram. In patients with MS+, hypertrophy of the left ventricular myocardium was detected according to echocardiogram even with a normal level of BP.

CONCLUSION: The presence of MS in patients with RA is associated with a higher activity of RA most of all because of pain syndrome. At the same time, pain syndrome correlates with the level of blood pressure. The combination of MS and RA leads to an increase of cardiovascular risk factors: cholesterol level and myocardial hypertrophy, which causes the need of using the echocardiography for this group of patients.

REFERENCE: [1] rheumatoid arthritis, metabolic syndrome.

Disclosure of Interests: None declared


THU0131

EFFECT OF METABOLIC SYNDROME ON THE COURSE OF RHEUMATOID ARTHRITIS AND CARDIOVASCULAR RISK

Svetlana Lapshina1,2, Luslia Feislabanova1, Luciya Kupenkova1, Ridiya Sharapatulidze1, Aigu Akeemtizeriano1, Kazan State Medical University, Kazan, Russian Federation; 2 Republic Clinical Hospital, Kazan, Russian Federation

BACKGROUND: Both rheumatoid arthritis (RA) and metabolic syndrome (MS) have an inflammatory component in the pathogenesis and both aggravate cardiovascular risks.

OBJECTIVES: The aim is to study the effect of MS on the course of RA and the increase in cardiovascular risk in these patients.

METHODS: 100 patients (men 7%, women 93%) aged 21 to 61 years (average age 55±12.4) with reliable RA were examined. High activity in DAS28 scale was observed in 68%, moderate - in 30%, low - in 2%, rheumatoid factor (RF) positivity - in 88%, ACCP - 81%. Disease-modifying anti-rheumatic drugs (DMARDs) were used by an experienced sonographer to all patients in order to detect the presence of atherosclerosis at baseline. Furthermore, in a subgroup of 19 patients, the parameters we previously reported (except for IMT) were compared between baseline and a 3-month follow-up. We also compared disease activity indexes (disease activity score (DAS28), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)) at these predefined time-points.

RESULTS: As regards the demographic characteristics of 19 RA patients, the mean (SD) age was 54.7 (14.0) years, disease duration was 4.5 (1.3) years, there were 11 (35.5%) men and 20 (64.5%) women and 6 (31.6%) smokers. As far as the immunological profile of patients is concerned, 17 (54.8%) were RF(+)- and 8 (25.8%) ACPA(+). The comparison of the parameters between RA patients and matched-controls revealed an increased IMT in RA patients (0.9 ± 0.17 mm vs 0.6 ± 0.13 mm; p<0.01), while the other parameters involving the lipid profile did not differ among the two groups. In the subgroup of 19 patients, there was a significant increase in mean (SD) HDL-C and ApoA1 levels from baseline to 3-month follow-up [55.3 (15.44) vs 61.68 (15.3) vs 63.16 (28.89) vs 73.11 (29.65) mmol/L respectively; p<0.05]. There was also a reduction in mean systolic blood pressure [137.89 (14.36) vs 130.53 (12.68); p<0.05], diastolic blood pressure [81.63 (6.8) vs 77.63 (6.99); p<0.05], ESR [25.53 (16.57) vs 19.84 (16.44); p<0.05] and DAS28 score [3.41 (1.14) vs 2.62 (1.12); p<0.05]. No